Introduction
Assessment of liver fibrosis in patients with chronic hepatitis C virus (HCV) infection is considered a relevant part of patient care, for decision making, and is an important prognostic factor [1,2].
In addition, the severity of liver fibrosis may be used as a selection criterion for antiviral therapy, duration of treatment, from severe fibrosis (F3-4).
Patients and Methods

Patients
This cross-sectional study conducted positive patients. Later, the study plan was discussed with patients and the biopsy was taken only from those patients who were willing for this procedure.
Patients' Consent
Informed written consent from each patient and local ethical committee 
Baseline assessment:
The patients were subjected to 
Liver Biopsy and Histo-pathological examination
The liver biopsy procedure, its advantages, and its possible adverse effects were explained to the patients. An informed consent to obtain a liver biopsy was 
Statistical Analysis
Results
Patient's data
According to METAVIR system, the determination of liver fibrosis showed stage F0 in 19 (3.1%), F1 in 372 (61.6%), 112 (18.5%) patients in F2 and 83 (13.7%) patients were F3 stage and 18 (3.0%) patients were F4 (Table 2 ). According to fibrosis stage, all patients were classified into two groups, the first group considered F0-2 as (non-severe fibrosis) and the second group considered F3-4 as (severe fibrosis).
Relationship between clinical findings and fibrosis
Liver fibrosis stages were statistically significant between age groups (p=0.000). 2614-2618.
Data expressed as mean SD or median (range).
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